NASDAQ:NUVA NuVasive (NUVA) Stock Price, News & Analysis → Protect Your Bank Account Before It’s Too Late (From Weiss Ratings) (Ad) Free NUVA Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$39.75▼$39.7550-Day Range$38.12▼$40.6652-Week Range$35.17▼$49.53VolumeN/AAverage Volume1.16 million shsMarket Capitalization$2.08 billionP/E Ratio79.50Dividend YieldN/APrice Target$51.33 Stock AnalysisStock Analysis Get NuVasive alerts: Email Address NuVasive MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside29.1% Upside$51.33 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings Growth16.67%From $2.22 to $2.59 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.97 out of 5 starsMedical Sector566th out of 909 stocksMedical Devices Industry5th out of 7 stocks 3.3 Analyst's Opinion Consensus RatingNuVasive has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Amount of Analyst CoverageNuVasive has received no research coverage in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for NUVA. Previous Next 0.0 Dividend Strength Dividend YieldNuVasive does not currently pay a dividend.Dividend GrowthNuVasive does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for NUVA. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for NuVasive this week, compared to 2 articles on an average week. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, NuVasive insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.53% of the stock of NuVasive is held by insiders. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for NuVasive are expected to grow by 16.67% in the coming year, from $2.22 to $2.59 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of NuVasive is 79.50, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 148.63.Price to Earnings Ratio vs. SectorThe P/E ratio of NuVasive is 79.50, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 267.25.Price to Book Value per Share RatioNuVasive has a P/B Ratio of 2.34. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad TradeSmithThe A.I. story nobody is telling you (Read ASAP)There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...Click here to see Louis' new video for yourself. About NuVasive Stock (NASDAQ:NUVA)NuVasive, Inc., a medical technology company, develops, manufactures, and sells procedural solutions for spine surgery. It provides surgical access instruments, including Maxcess integrated split-blade retractor system that enable less-invasive surgical techniques by minimizing soft tissue disruption during spine surgery; specialized spinal implants to advance spinal fusion by enhancing the osseointegration and biomechanical properties of implant materials, including porous titanium and porous polyetheretherketone; and fixation system that facilitates the preservation and restoration of patient alignment. The company also offers cervical total disc replacement technology for cervical spinal fusion surgery; neuromonitoring systems, which use proprietary software-driven nerve detection and avoidance technology, and its intraoperative neuromonitoring services and support; and Pulse platform, a software ecosystem that integrates multiple hardware technologies into a single, condensed footprint in the operating room. In addition, it provides expandable growing rod implant systems for the treatment of early-onset scoliosis; various biologics that are used to aid in the spinal fusion or bone healing process; Precice, an intramedullary device that utilizes the MAGEC technology to non-invasively lengthen the femur and tibia; and onsite and remote monitoring of the neurological systems of patients undergoing spinal and brain-related surgeries. The company sells its products to patients, surgeons, hospitals, and insurers through independent sales agents, directly employed sales personnel, and distributors in the United States and internationally. NuVasive, Inc. was incorporated in 1997 and is headquartered in San Diego, California. As of September 1, 2023, NuVasive, Inc. operates as a subsidiary of Globus Medical, Inc.Read More Ad TradeSmithThe A.I. story nobody is telling you (Read ASAP)There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...Click here to see Louis' new video for yourself. NUVA Stock News HeadlinesApril 17, 2024 | finance.yahoo.comSMAIO Publishes its 2023 Annual ResultsApril 9, 2024 | finance.yahoo.comGlobal Polymeric Biomaterials Market 10 Year Forecast Report 2024-2034, with Company Profiles of the Top 10+ Major Market PlayersApril 24, 2024 | GoldenCrest Metals (Ad)Exposed: How Big Banks Plan to Chain Your Wealth with Digital DollarsBig Banks have declared war on your wallet. But it's not too late to fight back. Discover how to protect your assets from their latest maneuver.April 3, 2024 | finance.yahoo.com$14.3 Bn Spinal Implants Markets: Devices, Biologics, Stimulators, VCF, Spinal Decompression, Fusion, Non-Fusion - Global Forecast to 2028March 13, 2024 | msn.comUK reinstates modified MAGEC X system for scoliosis treatmentsMarch 12, 2024 | finance.yahoo.comOrthobiologics Market Set to Reach $8.2 Billion by 2030, Viscosupplementation Segment Exhibiting Robust GrowthMarch 12, 2024 | finanznachrichten.deMinimally Invasive Surgery Market Worth $74.6 billion | MarketsandMarketsMarch 5, 2024 | finance.yahoo.comJ. Kurt Jacobus, Ph.D. Joins CurvaFix Board of DirectorsApril 24, 2024 | GoldenCrest Metals (Ad)Exposed: How Big Banks Plan to Chain Your Wealth with Digital DollarsBig Banks have declared war on your wallet. But it's not too late to fight back. Discover how to protect your assets from their latest maneuver.February 21, 2024 | uk.finance.yahoo.comQ4 2023 Globus Medical Inc Earnings CallFebruary 21, 2024 | markets.businessinsider.comGlobus Medical: Hold Rating Affirmed Amidst Modest Growth Projections and Integration RisksFebruary 13, 2024 | markets.businessinsider.comGlobus Medical Schedules Fourth Quarter and Full Year 2023 Earnings Release and Conference CallFebruary 5, 2024 | finance.yahoo.comGlobus Medical promotes Keith Pfeil to Chief Operating Officer and Chief Financial OfficerJanuary 26, 2024 | finance.yahoo.comGlobus lays off Nuvasive employees after mergerJanuary 25, 2024 | finanznachrichten.deCoherent Market Insights: Global Sacroiliac Joint Fusion Market to Reach US$ 1,525.1 Million by 2030, Rising at a CAGR of 13.6% | Report by CoherentMIJanuary 25, 2024 | finance.yahoo.comImplanet Announces the Appointment of Max W. Painter as Vice-President and General Manager of its US SubsidiaryJanuary 25, 2024 | finanznachrichten.deSpinal Implants Market Worth $14.3 Billion | MarketsandMarketsJanuary 23, 2024 | finanznachrichten.deSMAIO: 2023 Sales up +120% to €5.4 MillionJanuary 23, 2024 | finance.yahoo.comOrthopedics leaders watch procedure backlog, new technologies in 2024January 23, 2024 | finance.yahoo.comHere's Why You Should Retain Globus Medical (GMED) Stock NowJanuary 17, 2024 | finance.yahoo.comNuvasive’s former CEO joins 3M spinoffJanuary 16, 2024 | finance.yahoo.comAmanda Bloom Joins Spineology as Executive Vice President of MarketingJanuary 16, 2024 | finance.yahoo.comLimbplastX Will Be One Of The Few Sites To Receive Nuvasive’s Exclusive Brand-New Precice Max Nail On February 26thJanuary 8, 2024 | finance.yahoo.comOrthofix Provides Executive Management Business Update and Appoints Julie Andrews as Chief Financial OfficerDecember 27, 2023 | msn.comFormer Buckeye Branden Bowen survived 'rough' time, now is 'really excited for the future'December 26, 2023 | bizjournals.com2023 in Review: Challenging year in health care brings surge of mergers and acquisitionsNovember 8, 2023 | markets.businessinsider.comPositive Outlook for Globus Medical Post-Merger: Analysis of Q3 Results and Future PlansSee More Headlines Receive NUVA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NuVasive and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/02/2023Today4/23/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical Devices Sub-IndustryHealth Care Equipment Current SymbolNASDAQ:NUVA CUSIP67070410 CIK1142596 Webwww.nuvasive.com Phone(858) 909-1800Fax800-475-9134Employees3,000Year Founded1997Price Target and Rating Average Stock Price Target$51.33 High Stock Price Target$58.00 Low Stock Price Target$45.00 Potential Upside/Downside+29.1%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)$0.50 Trailing P/E Ratio79.50 Forward P/E Ratio17.91 P/E GrowthN/ANet Income$40.41 million Net Margins2.32% Pretax Margin3.41% Return on Equity12.17% Return on Assets4.88% Debt Debt-to-Equity Ratio0.50 Current Ratio1.25 Quick Ratio0.65 Sales & Book Value Annual Sales$1.23 billion Price / Sales1.70 Cash Flow$4.96 per share Price / Cash Flow8.01 Book Value$17.02 per share Price / Book2.34Miscellaneous Outstanding Shares52,449,000Free Float52,171,000Market Cap$2.08 billion OptionableOptionable Beta1.07 Social Links Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. J. Christopher Barry (Age 50)CEO & Director Comp: $3.08MMr. Matthew K. Harbaugh (Age 53)Principal Accounting Officer, CFO & Exec. VP Comp: $1.37MMr. Dale A. Wolf (Age 43)Sr. VP of Global Operations Comp: $782.6kMr. Nathaniel B. Sisitsky Esq. (Age 48)Sr. VP, Gen. Counsel & Corp. Sec. Comp: $842.84kMr. Michael Farrington (Age 39)Sr. VP of People & Culture Comp: $626.46kMr. Ryan DonahoeSr. VP & Chief Technology OfficerMs. Juliet C. CunninghamVP of Investor RelationsMr. Sean FreemanSr. VP of Strategy & Corp. Devel.Ms. Lisa PecoraVP & Head of Global Commercial Fin.Ms. Aviva McPherronSr. VP of Information TechnologyMore ExecutivesKey CompetitorsICU MedicalNASDAQ:ICUIAtriCureNASDAQ:ATRCAxonicsNASDAQ:AXNXSilk Road MedicalNASDAQ:SILKCantel MedicalNYSE:CMDView All CompetitorsInstitutional OwnershipNew Mexico Educational Retirement BoardBought 10,700 shares on 4/23/2024Ownership: 0.020%View All Institutional Transactions NUVA Stock Analysis - Frequently Asked Questions Should I buy or sell NuVasive stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NuVasive in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" NUVA shares. View NUVA analyst ratings or view top-rated stocks. What is NuVasive's stock price target for 2024? 2 Wall Street analysts have issued 1 year target prices for NuVasive's stock. Their NUVA share price targets range from $45.00 to $58.00. On average, they anticipate the company's share price to reach $51.33 in the next twelve months. This suggests a possible upside of 29.1% from the stock's current price. View analysts price targets for NUVA or view top-rated stocks among Wall Street analysts. How were NuVasive's earnings last quarter? NuVasive, Inc. (NASDAQ:NUVA) issued its quarterly earnings data on Wednesday, August, 2nd. The medical device company reported $0.56 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $0.56. The medical device company earned $317.80 million during the quarter, compared to the consensus estimate of $322.53 million. NuVasive had a trailing twelve-month return on equity of 12.17% and a net margin of 2.32%. The business's revenue was up 2.4% on a year-over-year basis. During the same period in the prior year, the business posted $0.47 earnings per share. What ETF holds NuVasive's stock? SPDR S&P 600 Small Cap ETF holds 96,888 shares of NUVA stock, representing 0.22% of its portfolio. What is Chris Barry's approval rating as NuVasive's CEO? 59 employees have rated NuVasive Chief Executive Officer Chris Barry on Glassdoor.com. Chris Barry has an approval rating of 88% among the company's employees. What other stocks do shareholders of NuVasive own? Based on aggregate information from My MarketBeat watchlists, some companies that other NuVasive investors own include BioMarin Pharmaceutical (BMRN), Incyte (INCY), Puma Biotechnology (PBYI), Intel (INTC), Alibaba Group (BABA), (MDVN) (MDVN), Micron Technology (MU), Bank of America (BAC), Gilead Sciences (GILD) and Applied Materials (AMAT). Who are NuVasive's major shareholders? NuVasive's stock is owned by many different institutional and retail investors. Top institutional shareholders include New Mexico Educational Retirement Board (0.02%). Insiders that own company stock include James Christopher Barry, Lucas Vitale and Massimo Calafiore. View institutional ownership trends. Does NuVasive have any subsidiaries? The following companies are subsidiares of NuVasive: Biotronic NeuroNetwork, Ellipse Technologies, NuVasive Clinical Services Monitoring Inc., NuVasive Japan KK, NuVasive Specialized Orthopedics Inc., NuVasive Technology International Limited, SafePassage, Simplify Medical, and Vertera Spine.Read More This page (NASDAQ:NUVA) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersSHOCKING Crypto Leak…Crypto 101 Mediatop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsThe #1 Crypto for 2024InvestorPlaceMan Who Predicted 2008: “This Will be Worse.”AltimetryBiden out June 13; Kamala won’t replace him?Paradigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NuVasive, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.